We conducted a RECIST 1.1 assessment on the treated patients and found that the HE4 levels in the PD group were significantly higher than those of patients in the CR, PR, and SD groups, which confirmed our conjecture and also showed that HE4 can be used as a prognostic monitoring indicator for lung cancer.28 The gene discussed is WFDC2; the disease is lung carcinoma.